<--- Back to Details
First PageDocument Content
Pharmaceuticals policy / Biosimilar / Biotechnology / Drugs / Generic drug / Food and Drug Administration / Test data exclusivity / Evergreening / Biologic / Pharmaceutical sciences / Pharmacology / Clinical research
Date: 2009-10-14 12:19:27
Pharmaceuticals policy
Biosimilar
Biotechnology
Drugs
Generic drug
Food and Drug Administration
Test data exclusivity
Evergreening
Biologic
Pharmaceutical sciences
Pharmacology
Clinical research

Add to Reading List

Source URL: www.healthlawyers.org

Download Document from Source Website

File Size: 102,78 KB

Share Document on Facebook

Similar Documents

Patent law / Pharmaceuticals policy / Monopoly / Pharmaceutical industry / First-mover advantage / Strategic management / Pharmaceutical industry in India / Pharmaceutical industry in China / Patent / Generic drug / Evergreening / TRIPS Agreement

Working Paper Series NoFIRST-MOVER ADVANTAGES BEFORE AND AFTER TRIPS Evidence from the Indian Pharmaceutical Industry Ajay Bhaskarabhatla

DocID: 1p6Uw - View Document

Evergreening / Technology / Pharmaceuticals policy / Pharmaceutical industry / Science / Pharmacology / Generic drug / Patent / Chemical patent / Patent law / Law / Pharmaceutical sciences

PDF Document

DocID: 1fWv5 - View Document

Civil law / International trade / World Trade Organization / Monopoly / Pharmaceuticals policy / Agreement on Trade-Related Aspects of Intellectual Property Rights / Evergreening / Doha Declaration / Patent / Patent law / Law / Intellectual property law

Submission to the Department of Foreign Affairs and Trade: The Trans Pacific Partnership Agreement, Intellectual Property and Medicines 1 October, 2013

DocID: 18yKo - View Document

Purines / Viral hepatitis / Hepatitis B / Lamivudine / Hepatitis C / Hepatocellular carcinoma / Viral disease / HBsAg / Evergreening / Medicine / Bristol-Myers Squibb / Entecavir

Entecavir and Hepatitis B Background on Hepatitis B Hepatitis B virus (HBV) is highly endemic in South Africa and across sub-Saharan Africa, where around 8% of people are chronically infected, and rates of HBV-related li

DocID: 18mXH - View Document

Pharmaceutical sciences / Business / Evergreening / Technology / Pharmacology / International trade / Patent law / Pharmaceuticals policy / Law

Australia and New Zealand Health Policy BioMed Central Open Access

DocID: 187up - View Document